Novo Nordisk bags CDSCO Panel nod to study Semaglutide - Video
|
Overview
In line with the drug major Novo-Nordisk's justification for anti-diabetic drug Semaglutide the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has given its nod to conduct the study.
This came after the firm presented the justification in the recommendation of the expert panel at the meeting of SEC for Endocrinology & Metabolism was held on 20.02.2022.
For more information, check out the link below:
NovoNordisk Gets CDSCO Panel Okay To Study Anti-Diabetic Drug Semaglutide
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
